alexa Case Reports on the Use of Intravenous Immunoglobulins (IVIG) in the Treatment of Systemic Lupus Erythematosus (SLE)
ISSN: 2165-7920

Journal of Clinical Case Reports
Open Access

OMICS International organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations

700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)

Case Report

Case Reports on the Use of Intravenous Immunoglobulins (IVIG) in the Treatment of Systemic Lupus Erythematosus (SLE)

Angel Alberto Justiz Vaillant1*, Niurka Ramirez2, Armando Cadiz3 and Patrick Eberechi Akpaka1
1Department of Para-Clinical Sciences, Faculty of Medical Sciences, The University of the West Indies, St. Augustine, Trinidad and Tobago
2Department of Internal Medicine, Freyre de Andrade Hospital, Havana City, Cuba
3Carlos J. Finlay Vaccine and Serum Institute, Havana, Cuba
Corresponding Author : Angel Alberto Justiz Vaillant, MD, PhD
Department of Para-Clinical Sciences
The University of the West Indies
St. Augustine, Trinidad and Tobago, Cuba
Tel: 868-645-2640/9, Ext. 2322/2330
Fax: 868-663-3797
E-mail: [email protected]
Received February 14, 2013; Accepted March 22, 2013; Published March 25, 2013
Citation: Vaillant AAJ, Ramirez N, Cadiz A, Akpaka PE (2013) Case Reports on the Use of Intravenous Immunoglobulins (IVIG) in the Treatment of Systemic Lupus Erythematosus (SLE). J Clin Case Rep 3:263. doi:10.4172/2165-7920.1000263
Copyright: © 2013 Vaillant AAJ, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Abstract

Introduction: This work represents a preliminary study of the treatment of systemic lupus erythematosus with a commercially available intravenous immunoglobulin. The aim of this study was to assess the efficacy of this product in three patients aged 16, 34 and 49 diagnosed with systemic lupus erythematosus at the Internal Medicine Service of “Freire de Andrade” Hospital, Cuba. Case report summary: The patients had a history of treatment with several drugs, including immunesuppressants. However recurrent respiratory tract infections, skin rash as well as several immunological abnormalities were present. Intravenous immunoglobulin (5-10 g/day) was given intravenously during five consecutive days, in the absence of other types of immunotherapy. An immunological profile before and after the intravenous immunoglobulin therapy was performed. In addition the patients were clinically evaluated using the Systemic Lupus Erythematosus Disease Activity Index (SLEDAI) score. The intravenous immunoglobulin therapy was highly effective in all patients due to its immunosuppressive, anti-inflammatory, immunomodulating and antimicrobial properties. It also prevented some of the frequent complications associated with the traditional immunotherapy in systemic lupus erythematosus. Conclusion: We recommend new clinical studies on large group of patients to establish the efficacy and side effects of intravenous immunoglobulin as a first line therapy in systemic lupus erythematosus.

Keywords

Share This Page

Additional Info

Loading
Loading Please wait..
 
Peer Reviewed Journals
 
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals
International Conferences 2017-18
 
Meet Inspiring Speakers and Experts at our 3000+ Global Annual Meetings

Contact Us

Agri & Aquaculture Journals

Dr. Krish

[email protected]

1-702-714-7001Extn: 9040

Biochemistry Journals

Datta A

[email protected]

1-702-714-7001Extn: 9037

Business & Management Journals

Ronald

[email protected]

1-702-714-7001Extn: 9042

Chemistry Journals

Gabriel Shaw

[email protected]

1-702-714-7001Extn: 9040

Clinical Journals

Datta A

[email protected]

1-702-714-7001Extn: 9037

Engineering Journals

James Franklin

[email protected]

1-702-714-7001Extn: 9042

Food & Nutrition Journals

Katie Wilson

[email protected]

1-702-714-7001Extn: 9042

General Science

Andrea Jason

[email protected]

1-702-714-7001Extn: 9043

Genetics & Molecular Biology Journals

Anna Melissa

[email protected]

1-702-714-7001Extn: 9006

Immunology & Microbiology Journals

David Gorantl

[email protected]

1-702-714-7001Extn: 9014

Materials Science Journals

Rachle Green

[email protected]

1-702-714-7001Extn: 9039

Nursing & Health Care Journals

Stephanie Skinner

[email protected]

1-702-714-7001Extn: 9039

Medical Journals

Nimmi Anna

[email protected]

1-702-714-7001Extn: 9038

Neuroscience & Psychology Journals

Nathan T

[email protected]

1-702-714-7001Extn: 9041

Pharmaceutical Sciences Journals

Ann Jose

[email protected]

1-702-714-7001Extn: 9007

Social & Political Science Journals

Steve Harry

[email protected]

1-702-714-7001Extn: 9042

 
© 2008- 2017 OMICS International - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version
adwords